The word ‘crisis’ has a wide range of meanings and it’s well used in the media to catch the reader’s attention. Lately, the terms ‘political crisis’, financial ‘crisis’ and ‘constitutional crisis’ appear almost daily in media headlines. In a previous life, the term ‘crisis management’ was used daily in the work I was undertaking as I went from problem to problem, dampening or putting out fires (….. that’s a metaphor!). Thinking back, my adrenaline (epinephrine), norepinephrine, and cortisol must have been very busy!
However, in the world of Neuroendocrine Tumours (NETs), ‘crisis’ has a very significant meaning and its very mention will make ears prick up. The word ‘crisis’ is normally spoken or written using the term ‘Carcinoid Crisis’ given this is the type of NET with which it has been mostly associated. However, I’ve studied and researched and it would appear that some form of ‘crisis’ might apply to other types of NETs. Perhaps this is another knock-on effect caused by the historical use of the word ‘Carcinoid’ to incorrectly refer to all NETs. In terms of ‘crisis’, maybe there should be a more generic NETs wide term? More on that later.
What is ‘Carcinoid Crisis’?
In the simplest of terms, it is a dangerous change in blood pressure, heart rate, and breathing (technical term – cardiopulmonary hemodynamic instability). On an operating table under anaesthetics or an invasive procedure such as liver embolization, this can actually be life threatening. Incidentally, this happens with many other types of conditions and it is the cause of the ‘cardiopulmonary hemodynamic instability’ that is different with NET patients. For some, it could be a life or death situation
Why does it happen to some NET Patients?
NETs can release a variety of ‘vasoactive peptides’ (hormones) in excess (e.g. serotonin, catecholamines, histamine). Under normal circumstances, these would just present as routine syndromes which may need to be controlled in most cases with somatostatin analogue treatment (Octreotide/Lanreotide).
Excess amounts of these vasoactive substances can cause both hypertension and hypotension (high and low blood pressure respectively). In extreme cases this can lead to what is known as a (carcinoid) crisis situation. It is said by one very well-known NET expert to “not to be something which happens randomly to all patients, it is usually linked to a medical procedure of some sort when you are having anaesthesia”. Dr Eric Liu also said “Luckily it is relatively uncommon”.
How is the risk managed?
If you research this plus perhaps from your own experience, you will know there are different ideas and ‘protocols’. However, they all mostly involve some pre-procedure infusion of a somatostatin analogue (normally Octreotide) – although I’d love to hear from anyone who has had Lanreotide as an alternative. Some doctors or hospitals are known to have their own ‘protocols’ and I’ve uploaded the one from the ISI NET book page 215 (Wang, Boudreaux, O’Dorisio, Vinik, Woltering, et al). Click here. Please note this is an example rather than a recommendation as this is something the NOLA team have developed for their own centre. In all the big procedures I’ve had done in my local NET Centre, I have always been admitted the day before to receive what they describe as an ‘Octreotide Soak’.
Patients are always asking about the risk and requirements for smaller procedures such as an Endoscopy. There does not seem to common guidance on this but Dr Woltering who is always forthcoming with advice suggests 200 micrograms of Octreotide before the procedure commences.
Dental visits involving anaesthetics can also be an issue and you can see Dr Woltering’s advice in my blog about the 5 Es of Carcinoid Syndrome. Additionally there is advice for users of ‘Epi Pens’. You also need to derisk those situations.
Carcinoid Syndrome vs Carcinoid Crisis
I have seen some discussion about the difference between a severe attack of carcinoid syndrome and carcinoid crisis and it’s a really difficult area. Looking at Dr Liu’s definition, he said it was ‘usually’ linked to a procedure based scenario so I guess it could happen in a non-surgical scenario in extreme cases. Most people are effectively managed on monthly injections of Octreotide/Lanreotide but some people still need ‘rescue shots’ (top ups) where they are experiencing breakthrough symptoms. When I was symptomatic (syndromic), I would regularly flush in stressful situations but that was definitely syndrome rather than crisis. Check out my video explaining how I felt. It’s worth reading something called the 5 E’s of Carcinoid Syndrome, probably useful to other types of NETs as I’m sure there is some overlap.
What about other types of NETs
The ISI Book Link above (here for convenience), does state “regardless of tumor type, all NETs should be pre-treated with Octreotide for protection against crisis“. I know that NET patients other than those with ‘Carcinoid Tumours’ are also treated with somatostatin analogues, as they too can be subject to the effects of excess secretion of certain vasoactive peptides. I recently read an article about a person with a Pheochromocytoma (a less common NET that comes from the chromaffin cells of the adrenal medulla and secretes catecholamines). The person had what was described as an ‘Intraoperative Hypertensive Crisis’ that appeared to be caused by her tumour type rather than the sort of incident that might occur in a standard surgery. Hypertension (high blood pressure) can be a symptom of Pheochromocytoma so you can see the problem with surgery and other procedures. An interesting issue with this type of NET is that after surgery, the patient is at risk for hypotension (low blood pressure) from venous dilation caused by the sudden withdrawal of catecholamines.
I highly suspect there are many examples from the NET world beyond the ‘carcinoid’ subtype of NETs and I’ve already given you one above. I’ll update this blog as I discover other examples. In the meantime, make sure you ask your medical team about ‘crisis protection’ if you are to undergo any surgical or invasive medical procedure.
Do we need to rename the term ‘Carcinoid Crisis’? Probably …… let’s give it a red card!
p.s. if you want one of these cards, contact NET Patient Foundation by email here firstname.lastname@example.org If you’re overseas, you may be asked to pay the postage.
Thanks for reading